AU2003213684C1 - Methods of inducing terminal differentiation - Google Patents

Methods of inducing terminal differentiation Download PDF

Info

Publication number
AU2003213684C1
AU2003213684C1 AU2003213684A AU2003213684A AU2003213684C1 AU 2003213684 C1 AU2003213684 C1 AU 2003213684C1 AU 2003213684 A AU2003213684 A AU 2003213684A AU 2003213684 A AU2003213684 A AU 2003213684A AU 2003213684 C1 AU2003213684 C1 AU 2003213684C1
Authority
AU
Australia
Prior art keywords
saha
pharmaceutically acceptable
hydrate
acceptable salt
hydroxamic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2003213684A
Other languages
English (en)
Other versions
AU2003213684A1 (en
AU2003213684B2 (en
Inventor
Judy H Chiao
W Kevin Kelly
Thomas A Miller
Victoria M. Richon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Merck HDAC Research LLC
Original Assignee
Sloan Kettering Institute for Cancer Research
Merck HDAC Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27805074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003213684(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Institute for Cancer Research, Merck HDAC Research LLC filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2003213684A1 publication Critical patent/AU2003213684A1/en
Publication of AU2003213684B2 publication Critical patent/AU2003213684B2/en
Assigned to MERCK HDAC RESEARCH, LLC, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH reassignment MERCK HDAC RESEARCH, LLC Request for Assignment Assignors: ATON PHARMA, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Priority to AU2007203525A priority Critical patent/AU2007203525C1/en
Application granted granted Critical
Publication of AU2003213684C1 publication Critical patent/AU2003213684C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
AU2003213684A 2002-03-04 2003-03-04 Methods of inducing terminal differentiation Active 2024-12-17 AU2003213684C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007203525A AU2007203525C1 (en) 2002-03-04 2007-07-26 Methods of Inducing Terminal Differentiation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36175902P 2002-03-04 2002-03-04
US60/361,759 2002-03-04
PCT/US2003/006451 WO2003075839A2 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007203525A Division AU2007203525C1 (en) 2002-03-04 2007-07-26 Methods of Inducing Terminal Differentiation

Publications (3)

Publication Number Publication Date
AU2003213684A1 AU2003213684A1 (en) 2003-09-22
AU2003213684B2 AU2003213684B2 (en) 2007-04-26
AU2003213684C1 true AU2003213684C1 (en) 2008-10-23

Family

ID=27805074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003213684A Active 2024-12-17 AU2003213684C1 (en) 2002-03-04 2003-03-04 Methods of inducing terminal differentiation

Country Status (18)

Country Link
US (7) US20040072735A1 (US20040072735A1-20040415-C00080.png)
EP (4) EP2266552A3 (US20040072735A1-20040415-C00080.png)
JP (4) JP4732693B2 (US20040072735A1-20040415-C00080.png)
KR (2) KR100892016B1 (US20040072735A1-20040415-C00080.png)
CN (3) CN1720034A (US20040072735A1-20040415-C00080.png)
AU (1) AU2003213684C1 (US20040072735A1-20040415-C00080.png)
BR (1) BR0308250A (US20040072735A1-20040415-C00080.png)
CA (3) CA2632078C (US20040072735A1-20040415-C00080.png)
ES (1) ES2532607T3 (US20040072735A1-20040415-C00080.png)
HK (1) HK1072362A1 (US20040072735A1-20040415-C00080.png)
IL (3) IL163909A0 (US20040072735A1-20040415-C00080.png)
MX (1) MXPA04008577A (US20040072735A1-20040415-C00080.png)
NO (2) NO329984B1 (US20040072735A1-20040415-C00080.png)
NZ (3) NZ535578A (US20040072735A1-20040415-C00080.png)
PL (1) PL372239A1 (US20040072735A1-20040415-C00080.png)
RU (3) RU2320331C2 (US20040072735A1-20040415-C00080.png)
WO (1) WO2003075839A2 (US20040072735A1-20040415-C00080.png)
ZA (2) ZA200407942B (US20040072735A1-20040415-C00080.png)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
EP2266552A3 (en) * 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
TW559390U (en) * 2002-08-27 2003-10-21 Molex Inc Electrical connector
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
KR20050022216A (ko) * 2003-08-25 2005-03-07 윤덕구 동결건조 즉석소면 및 그 제조방법
BRPI0413826A (pt) * 2003-08-26 2006-10-24 Aton Pharma Inc processo de tratamento de cáncer com inibidores de hdac
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
MX2007001550A (es) * 2004-08-09 2007-04-10 Astellas Pharma Inc Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac).
KR100848073B1 (ko) * 2004-12-14 2008-07-24 주식회사바이오러넥스 Ｒｕｎｘ2를 아세틸화하여 Ｒｕｎｘ2 활성을증가시킴으로써 ＢＭＰ에 의한 골형성 경로를 활성화시키는방법
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
BRPI0606480A (pt) * 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
AU2006207322A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2006082428A2 (en) 2005-02-03 2006-08-10 Topotarget Uk Limited Combination therapies using hdac inhibitors
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
US20090182019A1 (en) * 2005-04-18 2009-07-16 The Johns Hopkins University Histone deacetylase inhibitors
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
WO2006117567A2 (en) * 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2494969B1 (en) 2005-05-13 2015-03-25 TopoTarget UK Limited Pharmaceutical formulations of HDAC inhibitors
EP2229941A1 (en) * 2005-05-20 2010-09-22 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
ZA200800901B (en) * 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2621560A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
WO2007117272A2 (en) * 2005-09-30 2007-10-18 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Methods for treatment of hemorrhagic shock and related disorders
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
CN101365440A (zh) * 2005-11-04 2009-02-11 默克公司 用saha、卡铂和紫杉醇治疗癌症的方法以及其他联合治疗
WO2007056162A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
BRPI0619158A2 (pt) * 2005-12-05 2011-09-20 Astrazeneca Ab processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
MX2008010462A (es) 2006-02-14 2009-04-17 Harvard College Inhibidores de histona desacetilasa.
CA2650520A1 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
EP2019674B1 (en) * 2006-05-03 2016-11-23 The President and Fellows of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2018366A4 (en) * 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
WO2008053131A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
CN107090482A (zh) * 2006-12-29 2017-08-25 细胞基因公司 制备Romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
EP2124916A1 (en) * 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
WO2009040517A2 (en) * 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
EP2597091B1 (en) * 2007-12-20 2016-04-20 Pharma Mar, S.A. Antitumoral Compounds
CN102083428A (zh) * 2008-03-07 2011-06-01 顶标公司 采用长时间连续输液Belinostat进行治疗的方法
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
CA2740559C (en) 2008-10-15 2016-02-16 Generics [Uk] Limited Improved process
CA2744448A1 (en) 2008-11-26 2010-06-03 Vinayak Gore Polymorphs
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
EP2236503B1 (en) 2009-04-03 2014-02-26 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
JP2013508458A (ja) 2009-10-26 2013-03-07 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド Ｆｔｓとｈｄａｃ阻害剤との組合せを用いたがん治療
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US20110194996A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Transport container for stabilized liquid samples
WO2011127467A1 (en) * 2010-04-09 2011-10-13 Companion Diagnostics, Inc. Devices, systems, and methods for biomarker stabilization
CN103154016A (zh) 2010-05-05 2013-06-12 特卫华妇女健康有限公司 使用具有逐渐降低的释放速率的单剂型减轻对象症状的方法
RU2016149485A (ru) 2010-07-12 2018-10-31 Селджин Корпорейшн Твердые формы ромидепсина и их применение
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
ES2647368T3 (es) * 2010-10-08 2017-12-21 Vib Vzw Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth
US20120164674A1 (en) * 2010-10-28 2012-06-28 Selinfreund Richard H Devices and washes for biomarker stabilization
CA2856722C (en) 2011-11-30 2022-11-22 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
CN102793693A (zh) * 2012-09-07 2012-11-28 天津医科大学 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
BR112015022604A2 (pt) 2013-03-14 2017-10-24 Genentech Inc usos de um modulador de modificador de cromatina e um antagonista de egfr
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103819364B (zh) * 2014-01-24 2015-12-02 中南大学 N-烃酰基环内酰胺衍生物的一锅合成方法
EP3247342A4 (en) 2015-01-23 2018-10-10 Temple University - Of The Commonwealth System of Higher Education Use of short chain fatty acids in cancer prevention
WO2016164392A1 (en) 2015-04-06 2016-10-13 The Johns Hopkins University A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells
CN105055386A (zh) * 2015-08-12 2015-11-18 天津医科大学总医院 伏立诺他用于制备免疫调节药物的应用
CN106187818B (zh) * 2016-06-27 2017-12-08 刘美新 一种制备抗癌药物伏立诺他的方法
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMER MATERIALS FOR DELIVERING SHORT CHAIN FATTY ACIDS TO THE INTESTINAL FOR HUMAN HEALTH APPLICATIONS AND DISEASE TREATMENT
CN114846012B (zh) 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451334B2 (en) * 1997-05-30 2002-09-17 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA622801A (en) 1961-06-27 L. Clark Robert Substituted benzimidazolones
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
JPS61251649A (ja) * 1985-04-05 1986-11-08 Mitsubishi Petrochem Co Ltd ジカルボン酸ジアニリドの製造法
US5608108A (en) 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
JPH11514857A (ja) 1995-09-20 1999-12-21 メルク エンド カンパニー インコーポレーテッド 抗原虫剤の標的としてのヒストンデアセチラーゼ
US6239178B1 (en) * 1996-05-17 2001-05-29 George Dimelow Alexander Lord Method of treating mammals
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
JPH10262694A (ja) 1997-03-28 1998-10-06 Sumitomo Forestry Co Ltd Ｂ細胞性リンパ腫の骨髄転移検査法
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
BR9908214A (pt) 1998-01-30 2000-11-28 Biogen Inc Tratamento para linfomas foliculares utilizando inibidores da via da linfotoxina (lt)
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
NZ510504A (en) * 1998-09-25 2003-09-26 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
PL348648A1 (en) 1998-10-13 2002-06-03 Fujisawa Pharmaceutical Co Cyclic tetrapeptide compound and use thereof
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
US6450992B1 (en) 1999-07-02 2002-09-17 Smith & Nephew, Inc. Cannula interface
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
UA74345C2 (uk) * 1999-09-08 2005-12-15 Слоан-Кеттерінг Інстітьют Фо Кансер Рісерч Засоби клітинної диференціації і інгібітори гістонової деацетилази та способи їх використання
US6673564B2 (en) 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
JP2003528074A (ja) * 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002022133A1 (en) * 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1328510B1 (en) 2000-09-29 2013-11-20 TopoTarget UK Limited (e)-n-hydroxy-3-(3-sulfamoyl-phenyl)-acrylamide compounds and their therapeutic use
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6533803B2 (en) * 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1532244A4 (en) * 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
BRPI0413826A (pt) * 2003-08-26 2006-10-24 Aton Pharma Inc processo de tratamento de cáncer com inibidores de hdac
EP2226072A1 (en) 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
CA2617623A1 (en) 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
WO2007056162A2 (en) 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
CN101365440A (zh) * 2005-11-04 2009-02-11 默克公司 用saha、卡铂和紫杉醇治疗癌症的方法以及其他联合治疗
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451334B2 (en) * 1997-05-30 2002-09-17 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders

Also Published As

Publication number Publication date
US7399787B2 (en) 2008-07-15
EP1487426A4 (en) 2007-09-19
NO332749B1 (no) 2013-01-07
IL197582A (en) 2014-05-28
EP2322160A1 (en) 2011-05-18
US20080114069A1 (en) 2008-05-15
ZA200601757B (en) 2007-11-28
CN1720034A (zh) 2006-01-11
KR20080041307A (ko) 2008-05-09
ES2532607T3 (es) 2015-03-30
US20040127522A1 (en) 2004-07-01
RU2320331C2 (ru) 2008-03-27
NO20044112L (no) 2004-11-30
IL163909A (en) 2010-12-30
EP2082737A3 (en) 2009-08-12
NO329984B1 (no) 2011-01-31
CN101259120A (zh) 2008-09-10
NZ550185A (en) 2008-10-31
ZA200407942B (en) 2006-05-31
CN101259120B (zh) 2012-07-04
EP2082737B1 (en) 2014-12-31
CA2671976A1 (en) 2003-09-18
US7732490B2 (en) 2010-06-08
RU2394022C2 (ru) 2010-07-10
CA2671976C (en) 2016-05-10
NZ535578A (en) 2008-03-28
JP4732693B2 (ja) 2011-07-27
HK1072362A1 (en) 2005-08-26
AU2003213684A1 (en) 2003-09-22
CN103393630A (zh) 2013-11-20
CA2478094A1 (en) 2003-09-18
US20120041067A1 (en) 2012-02-16
AU2003213684B2 (en) 2007-04-26
US20080119562A1 (en) 2008-05-22
US20040072735A1 (en) 2004-04-15
US8067472B2 (en) 2011-11-29
BR0308250A (pt) 2005-01-11
IL163909A0 (en) 2005-12-18
JP2005525369A (ja) 2005-08-25
EP2082737A2 (en) 2009-07-29
EP2266552A2 (en) 2010-12-29
RU2004133675A (ru) 2005-08-10
WO2003075839A3 (en) 2003-12-31
WO2003075839A2 (en) 2003-09-18
NO20092714L (no) 2004-10-11
US20100210729A1 (en) 2010-08-19
RU2530648C2 (ru) 2014-10-10
JP2010001302A (ja) 2010-01-07
CA2632078C (en) 2012-08-14
JP5586896B2 (ja) 2014-09-10
EP1487426B1 (en) 2012-08-22
JP5675071B2 (ja) 2015-02-25
KR20070057794A (ko) 2007-06-07
CA2632078A1 (en) 2003-09-18
RU2007112879A (ru) 2008-10-20
JP2010006822A (ja) 2010-01-14
US20040127523A1 (en) 2004-07-01
PL372239A1 (en) 2005-07-11
KR100868813B1 (ko) 2008-11-14
IL197582A0 (en) 2009-12-24
MXPA04008577A (es) 2005-07-13
NZ567758A (en) 2009-07-31
CA2478094C (en) 2010-11-23
JP2014237669A (ja) 2014-12-18
EP2266552A3 (en) 2011-03-02
RU2010108448A (ru) 2011-09-20
KR100892016B1 (ko) 2009-04-07
EP1487426A2 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
AU2003213684C1 (en) Methods of inducing terminal differentiation
US7375137B2 (en) Methods of treating cancer with HDAC inhibitors
US8101663B2 (en) Polymorphs of suberoylanilide hydroxamic acid
US20090012175A1 (en) Methods of treating cancer with HDAC inhibitors
AU2007203525B2 (en) Methods of Inducing Terminal Differentiation
Richon et al. Methods of treating Hodgkin's and non-Hodgkin's lymphoma
NZ568678A (en) Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA)

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAMES TO READ MILLER, THOMAS A; RICHON, VICTORIA,M; CHIAO, JUDY H AND KELLY, W KEVIN

PC1 Assignment before grant (sect. 113)

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH; MER

Free format text: FORMER APPLICANT(S): SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH; ATON PHARMA, INC.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAY 2008.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAY 2008

NC Extension of term for standard patent requested (sect. 70)

Free format text: THE FOLLOWING APPLICATION(S) FOR EXTENSION OF TERM UNDER SECTION 70 HAVE BEEN MADE AND ARE OPEN FORPUBLIC INSPECTION.

PC Assignment registered

Free format text: FORMER OWNER WAS: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH; MERCK HDAC RESEARCH, LLC THE EARLIEST FIRST REGULATORY APPROVAL DATE PROVIDED BY THE PATENTEE 17 DEC 2009 FOR THE GOODS ZOLINZA VORINOSTAT ADDRESS FOR SERVICE IN AUSTRALIA: CULLENS PATENT AND TRADE MARK ATTORNEYS LEVEL 32 239 GEORGE STREET BRISBANE QLD 4000

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ZOLINZA VORINOSTAT

Filing date: 20091217

Extension date: 20241217